Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Multiple Oral Administration of HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects

NCT06520540 is registered in ClinicalTrials.gov with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06520540
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06520540 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Multiple Oral Administration of HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects
Lead sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
July 28, 2024
Completion date
December 30, 2024
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glucagon-like peptide-1 receptor agonists